

Originalbeiträge in Fachzeitschriften (peer-reviewed)

Wolf S, Zechmeister-Koss I, **Grössmann N**, Wild C (2019): Evaluating options for decision-making on costly hospital drugs in Austria. International Journal of Technology Assessment in Health Care. Submitted.

Grössmann N, Robausch M, Rothschedl E, Wild C, Simon J (2019): Published evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015. European Journal of Cancer. Submitted.

Kaur R, Surala M, Hoger S, **Grössmann N**, Grimm A, Timaeus L, Kallina W, Hummel T (2019): Pioneer interneurons instruct bilaterality in the Drosophila olfactory sensory map. Science Advances 2019; 5(10):eaaw5537.

Grössmann N, Wolf S, Rosian K, Wild C (2018): Pre-reimbursement: Early assessment for coverage decisions. Wiener Medizinische Wochenschrift 2019; Ausgabe 11-12/2019.

Grössmann N, Robausch M, Rosian K, Wild C, Simon J (2019): Monitoring evidence on overall survival benefits of anti-cancer drugs approved by the European Medicines Agency between 2009 and 2015. European Journal of Cancer 2019; 110:1-7.

Emprechtlinger R, **Grössmann N**, C Wild (2018): ESMO-MCBS v1.1: statistical and patient-relevant shortcomings. Annals of Oncology 2018; 29 (4): 1070-1071.

Grössmann N, Del Paggio J C, Wolf S, Sullivan R, Booth C M, Rosian K, Emprechtlinger R, Wild C (2017): Five years of EMA-approved systemic cancer therapies for solid tumours – a comparison of two thresholds for meaningful clinical benefit. European Journal of Cancer 2017; 82:66-71.

Grössmann N and Wild C (2016): 134 novel anti-cancer therapies were approved between Jan 2009 and April 2016: What is the level of knowledge concerning the clinical benefit at the time of approval? ESMO Open 2017; 1(6).

Wild C, **Grössmann N**, Bonanno PV, Bucsics A, Furst J, Garuoliene K, Godman B, Gulbinovič J, Jones J, Pomorski MK, Emprechtlinger R (2016): Utilisation of the ESMO-MCBS in practice of HTA. Annals of Oncology 2016; 27(11):2134-2136.

Wissenschaftliche Gutachten/ Forschungsberichte/ Buchbeiträge/ Monographien

Wild C und **Grössmann N** (2019): FoundationOne®CDx: Bestimmung von genetischen Profilen solider Tumore. Rapid Assessment 014.

Stanak M, **Grössman N** und Strohmaier C (2019): 177Lu-PSMA zur Behandlung von metastasierten kastrationsresistenten Prostatakarzinom. Decision Support Document 118.

Rosian K, Fischer S, **Grössmann N** (2018): Inhalationssedierung mit Lachgas (N₂O) in der Zahnmedizin – Organisatorische und berufsrechtliche Aspekte sowie ein systematischer Review zu Wirksamkeit und Sicherheit. LBI-HTA Projektbericht Nr.: 105. Wien: Ludwig Boltzmann Institut für Health Technology Assessment.

Fuchs S, **Grössmann N**, Eckhardt H, Busse R, Wild C (2018): PET/PET-CT Evidenz zum Bedarf und zur Planung in Deutschland und Österreich. HTA Projektbericht Nr. 77 update.

Grössmann N (2017): Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 72.

Grössmann N (2017): Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC). DSD: Horizon Scanning in Oncology 70.

Grössmann N and Wolf S (2017): Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.

Wolf S and **Grössmann N** (2017): Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer. DSD: Horizon Scanning in Oncology 65.

Grössmann N (2016): Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM). DSD: Horizon Scanning in Oncology 63.

Grössmann N (2016): Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion. DSD: Horizon Scanning in Oncology 62.

Grössmann N (2016): Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL). DSD: Horizon Scanning in Oncology 60.

Baumann M, **Grössmann N** (2016): Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 58.

Grössmann N, Baumann M (2016): Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 57.

Grössmann N, Wild C, Mayer J (2016): Onkologika: Übersicht zu Nutzenbewertungen und Refundierungspolitiken in Europa. Rapid Assessment 008.

Populärwissenschaftliche Artikel/ Newsletterbeiträge

Grössmann N und Robausch M (2019): Klinischer Nutzen onkologischer Arzneimittel nach europäischer Zulassung. Top Tipps NÖGKK; Ausgabe 03/2019.

Grössmann N (2019): Patientenrelevante Endpunkte und klinischer Nutzen von systemischen Krebstherapien. QUALITAS – Zeitschrift für Qualität und Entwicklung in Gesundheitseinrichtungen. Ausgabe 03/2019.

Grössmann N und Wild C (2019): Was nützen Krebsmedikamente? im dialog; 3/2019.

Grössmann N (2019): Darmkrebs Früherkennung per Stuhl-DNA Test. HTA-Newsletter Oktober 2019.

Grössmann N (2018): Positronen-Emissions-Tomographie – bedarfsgerechte und evidenzbasierte Planungsunterstützung. QUALITAS – Zeitschrift für Qualität und Entwicklung in Gesundheitseinrichtungen. Ausgabe 04/2018

Grössmann N (2018): PET/PET-CT Evidenz zum Bedarf und zur Planung in Deutschland und Österreich. HTA-Newsletter Oktober 2018.

Grössmann N (2018): Medizinische Genomik in der klinischen Routine. HTA-Newsletter Juni 2018.

Grössmann N (2018): „BeNeFIT“ – belgisch-niederländische Förderung von vergleichenden, praxisorientierten Studien. HTA-Newsletter April 2018.

Grössmann N (2017): Horizon Scanning und Frühbewertung – länderübergreifende Zusammenarbeit bei Arzneimitteln. HTA-Newsletter September 2017.

Grössmann N (2017): Methode zur Bewertung von regenerativer Medizin und Zelltherapie. HTA-Newsletter Juni 2017.

Grössmann N (2016): Klinischer Nutzen und Refundierungspolitiken hochpreisiger Onkologika. QUALITAS – Zeitschrift für Qualität und Entwicklung in Gesundheitseinrichtungen. Ausgabe 04/2016.

Grössmann N (2016): Multiples Myelom: Kosteneffektivität von 6 neuen Behandlungsregimen. HTA-Newsletter September 2016.

Grössmann N (2016): Klinischer Nutzen neuer Onkologika und Refundierungspolitiken. HTA-Newsletter Juli/August 2016.

Grössmann N (2016): Vergleich zielgerichteter Therapien bei inoperablem/metastasiertem Melanom. HTA-Newsletter März 2016.

Grössmann N (2016): Biomarker-basierte Therapieentscheidungen bei Brustkrebs-PatientInnen. HTA-Newsletter Februar 2016.

Vorträge

Grössmann N, Robausch M, Rosian K, Wild C, Simon J (2019): Monitoring evidence on overall survival benefits of anti-cancer drugs approved by the European Medicines Agency between 2009 and 2015. HTAi 2019, Annual Meeting; Cologne, 15.-19.06. 2019.

Grössmann N, Robausch M, Rosian K, Wild C, Simon J (2019): Monitoring evidence on overall survival benefits of anti-cancer drugs approved by the European Medicines Agency between 2009 and 2015. 15th YSA PhD Symposium; Vienna, 13.-14.06.2018.

Grössmann N, Robausch M, Rosian K, Wild C, Simon J (2019): Monitoring evidence on overall survival benefits of anti-cancer drugs approved by the European Medicines Agency between 2009 and 2015. 20. Jahrestagung des EbM-Netzwerks; Berlin, 21.-23.03.2019.

Grössmann N, Del Paggio J C, Wolf S, Sullivan R, Booth C M, Rosian K, Emprechtlinger R, Wild C (2018): Five years of EMA-approved systemic cancer therapies for solid tumours – a comparison of two thresholds for meaningful clinical benefit. LBG Meeting for Health Sciences; Wien, 29.-30.11.2018.

Grössmann N, Del Paggio J C, Wolf S, Sullivan R, Booth C M, Rosian K, Emprechtlinger R, Wild C (2018): Five years of EMA-approved systemic cancer therapies for solid

tumours – a comparison of two thresholds for meaningful clinical benefit. 6th International Conference on Preventing Overdiagnosis; Kopenhagen, 20.-22.08.2018.

Grössmann N (2018): Tools for making better informed decisions: Health Technology Assessment (HTA) & Horizon Scanning (HS). 3rd Summer School: Pharmaceutical Pricing and Reimbursement Policies; Wien, 23.-27.07.2018.

Grössmann N, Del Paggio J C, Wolf S, Sullivan R, Booth C M, Rosian K, Emprechtlinger R, Wild C (2018): EMA-approved systemic cancer therapies – a systematic analysis on the clinical benefit at the time of marketing authorisation & post-approval. 14th YSA PhD Symposium; Wien, 07.-08.06.2018.

Grössmann N (2018): Bridging the efficacy/effectiveness gap (part 2). 23rd EAHP Congress; Göteborg, 21.-23.03.2018

Grössmann N, Del Paggio J C, Wolf S, Sullivan R, Booth C M, Rosian K, Emprechtlinger R, Wild C (2018): Five years of EMA-approved systemic cancer therapies for solid tumours - a comparison of two thresholds for meaningful clinical benefit. 19. Jahrestagung des EbM-Netzwerks; Graz, 08.-10.03.2018.

Grössmann N (2017): Tools for making better informed decisions: Health Technology Assessment (HTA) & Horizon Scanning (HS). 2nd Summer School: Pharmaceutical Pricing and Reimbursement Policies; Wien, 28.08.-01.09.2017.

Grössmann N, Wild C (2017): Clinical benefit of oncological therapies at the time of approval. HTAi 2017, Annual Meeting; Rom: 17.-21.06 2017

Grössmann N, Wild C (2017): 134 novel anti-cancer therapies were approved between Jan 2009 and April 2016: What is the level of knowledge concerning the clinical benefit at the time of approval? EbM-Kongress 2017, 18. Jahrestagung; Hamburg: 09.-11.03.2017

Grössmann N, Wild C (2016): 134 novel anti-cancer therapies were approved between Jan 2009 and April 2016: What is the level of knowledge at the time of approval? LBG Meeting for Health Science 2016; Wien: 28.-29.11.2016

Posterpräsentationen

Grössmann N, Wild C (2016): 134 novel anti-cancer therapies were approved between January 2009 and April 2016: What do we actually know about oncological therapies at the time of approval? 4th International Conference on Preventing Overdiagnosis; Barcelona: 20.-22.09.2016

Grössmann N, Robausch M, Rosian K, Wild C, Simon J (2019): Monitoring evidence on overall survival benefits of anti-cancer drugs approved by the European Medicines Agency between 2009 and 2015. 4th PPRI Conference; Vienna, 23.-24.10.2019.